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Objective: Primary hyperparathyroidism (PHPT) is a common endocrine disorder in women which becomes more prevalent after menopause. In this study, we compared the demographic, clinical, and
biochemical variables between premenopausal (pre-M) and postmenopausal (post-M) women with
PHPT.
Methods: A retrospective analysis (from 2005 to 2019) of enrolled women PHPT patients from an online
Indian PHPT registry.
Results: Of the women with PHPT, 232 and 122 were pre-M and post-M, respectively. The number of
post-M PHPT cases registered had a 3.3-fold increase in 2015-2019 from 2005-2009 compared with only
a 2.5-fold increase in pre-M cases in the same duration. The majority were symptomatic (90%), although
pre-M had a higher proportion of symptomatic than post-M (92% vs 85%; P ¼ .04). Pre-M women showed
more prevalence of osteitis ﬁbrosa cystica than post-M women (28% vs 13%; P ¼ .03), although hypertension and gallstone disease were seen more frequently in post-M PHPT women. Pre-M women had a
signiﬁcantly higher median PTH (403 vs 246 pg/mL; P ¼ .02) and median alkaline phosphatase (202 vs
145 pg/mL; P ¼ .02) than post-M women, and vitamin D deﬁciency was more common in pre-M women
(58% vs 45%; P ¼ .03). Gland localization, tumor weight, and disease cure rates did not differ according to
menopausal status.
Conclusion: PHPT was more prevalent in pre-M women, although the number of post-M cases had
signiﬁcantly increased in the last 10 years. Pre-M women had generally more severe clinical and
biochemical variables than post-M PHPT women.
© 2020 AACE. Published by Elsevier Inc. All rights reserved.
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Introduction
Primary hyperparathyroidism (PHPT) is a systemic disease
characterized by hypercalcemia and an excessive secretion of

Abbreviations: ALP, alanine phosphatase; BMI, body mass index; iPTH, intact
parathyroid hormone; OFC, osteitis ﬁbrosa cystica; PHPT, primary hyperparathyroidism; post-M, postmenopausal; pre-M, premenopausal; PTH, parathyroid hormone; 25-OHD, 25-hydroxyvitamin D.
* Address correspondence and reprint requests to Dr Sanjay Kumar Bhadada,
Professor, Department of Endocrinology Postgraduate Institute of Medical Education and Research, Chandigarh e 160012, India.
E-mail address: bhadadask@rediffmail.com (S.K. Bhadada).
https://doi.org/10.1016/j.eprac.2020.12.012
1530-891X/© 2020 AACE. Published by Elsevier Inc. All rights reserved.

parathyroid hormone (PTH).1 Its clinical presentation in Western
countries is mostly asymptomatic probably because of the routine
use of multichannel chemistry picking up most patients in the
presymptomatic stage. However, in the Indian subcontinent, the
disease is still predominantly diagnosed with moderate to severe
clinical symptoms, with bone disease, renal involvement, weakness
and fatigue, gastrointestinal as well as neuropsychiatric symptoms.2-6
Women worldwide are approximately 3 times more frequently
affected by PHPT than men. In Western populations, postmenopausal (post-M) women make a signiﬁcant proportion of
PHPT patients. However, in India, PHPT is often diagnosed at a
younger age than their Western counterparts.6-10 Only a handful of
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consistent normalization of serum calcium after surgery, patients
were labeled as cured and all patients were supplemented with
vitamin D. The decision of surgery for asymptomatic patient were
based on the Third and Fourth International Workshop Guidelines
for the management of PHPT.19,20

studies have evaluated the difference in the disease based on
gender. Renal stones appear to be more common in men and bone
disease more common in women.11-14 To the best of our knowledge,
only 2 studies have explored the effect of menopause on the presentation of PHPT.15,16 Castellano et al15 reported that premenopausal (pre-M) women had a higher frequency of renal stones and
more clinical symptoms than post-M women with PHPT. Meng
et al16 found that post-M women in the USA had a higher prevalence of PHPT than those in China.
In the current study, we evaluated the changing trend of the
demographic, clinical presentation, and biochemical proﬁle of
women with PHPT in the last 25 years from the Indian PHPT registry and compared these parameters between pre-M and post-M
PHPT patients.

Statistical Analysis
All analyses were performed using the Statistical Package for the
Social Sciences version 20. Variables were preliminarily tested for
normal distribution using the Shapiro-Wilk W test. Normally
distributed data were presented as mean ± SD, and skewed data
were presented as median with interquartile range or otherwise, as
described. Continuous variables with normal distribution were
analyzed using the Student’s t test, and skewed data were analyzed
using the Mann-Whitney U test. Differences in categorical variables
were analyzed using the chi-square test. Linear regression analysis
was performed to correlate the biochemical factors, such as serum
calcium, PTH, ALP, and 25-hydroxyvitamin D (25-OHD), with the
adenoma weight. A P value < .05 was considered statistically
signiﬁcant.

Methods
Subjects
The
national online
Indian
PHPT registry
(www.
indianphptregistry.com) was started at the Department of Endocrinology, Postgraduate Institute of Medical Education and
Research (PGIMER), Chandigarh. The study was approved by the
Institutional Ethics Committee of PGIMER, Chandigarh, India. PHPT
patients only visiting PGIMER, Chandigarh center were included in
the current study. Clinically suspected patients of PHPT and patients found to have hypercalcemia with high PTH during routine
biochemical screening were evaluated, and conﬁrmed PHPT patients were enrolled in the Indian PHPT registry. Written and
informed consent was obtained from each study participant. The
diagnosis of PHPT was established by the presence of hypercalcemia (albumin corrected serum calcium >10.2 mg/dL, at least twice
24 h apart) and inappropriately elevated PTH levels (> 65 pg/mL) or
normocalcemic patients with elevated intact parathyroid hormone
(iPTH) levels. Patients diagnosed with familial PHPT (n ¼ 16) and
secondary renal hyperparathyroidism (n ¼ 23) were excluded from
the current study. Of 472 PHPT cases, 354 were women. The demographic, clinical features, biochemical measurements, and
postparathyroidectomy data were extracted from the registry,
analyzed, and compared between pre-M and post-M women.
Menopause was clinically deﬁned as the absence of menstruation
for more than 1 year.17
Demographic data extracted from the registry included age,
height, weight, and body mass index (BMI). Radiographic evaluation performed by skeletal survey, looking for fracture, osteitis
ﬁbrosa cystica (OFC), subperiosteal resorption, and ‘salt and pepper’
appearance of the skull, were recorded. Renal manifestations were
conﬁrmed by the history of stone or using ultrasound or noncontrast computerized tomography of the kidney, ureter, and
bladder for the presence of nephrolithiasis and/or nephrocalcinosis.
Biochemical parameters, such as serum calcium (RR, 8.6-10.2
mg/dL), inorganic phosphate (RR, 2.7-4.5 mg/dL), albumin (RR, 3.44.8 mg/dL), alkaline phosphatase (ALP) (RR, 40-129 IU/L), and
creatinine (RR, 0.6-1.3 mg/dL), were measured by an autoanalyzer
(Modular P800, Roche Diagnostics). Serum iPTH and 25hydroxyvitamin
D
were
measured
by
an
electrochemiluminescence assay (Elecsys 2010, Roche Diagnostics).
Vitamin D deﬁciency was deﬁned as a serum 25-hydroxyvitamin D
<20 ng/mL. Antibodies used in the PTH assay has <0.1% cross
reactivity with osteocalcin, b-cross laps, bone speciﬁc ALP as well as
PTH fragments PTH (1-34) and PTH (7-84).18
The parathyroid lesion was localized by neck ultrasonography
and/or dual-phase (99m)Tc-sestamibi planar followed by surgery of
imaging-conﬁrmed cases with a histopathological conﬁrmation of
parathyroid adenoma/hyperplasia/carcinoma. After achieving a

Results
Of 405 women with PHPT recruited during 2005-2019 (15
years), 232 were pre-M (65.5%) and 122 (34.5%) were post-M. We
evaluated the trend of pre-M and post-M registrations in 5-year
clusters. The total number of registrations increased in each time
period; however, the rate of increase was greater for post-M
women. Therefore, the average age of registrants increased over
time (Fig. 1). Overall, post-M patients showed a 3.2-fold increase
compared with the only 2.5-fold increase in pre-M PHPT patients
during the 2015-2019 compared with 2005-2009.

Comparison Between Pre-M and Post-M PHPT Patients
Demographic Features
The mean BMI was 24.4 ± 5.7 kg/m2. Post-M women had a
signiﬁcantly higher BMI (25.5 ± 5.8 vs 23.9 ± 5.5 kg/m2; P ¼ .03)
than pre-M women.

Clinical Features
Ninety percent (n ¼ 317) had 1 or more clinical symptoms of
PHPT, although there were more asymptomatic post-M women
(15% vs 8%; P ¼ .04). The most common clinical manifestation was
bone disease (n ¼ 213; 60%), followed by weakness and fatigue (n ¼
208; 59%), anemia (n ¼ 200; 57%), renal manifestations (n ¼ 177;
50%), hypertension (n ¼ 122; 35%), abdominal pain (n ¼ 96; 27%),
gallstone disease (GSD) (n ¼ 79; 22%), proximal myopathy (n ¼ 49;
14%), and pancreatitis (n ¼ 32; 9%).
Skeletal manifestations (bone pain, osteoporosis, fracture in
long bones and spine or OFC) were observed in 141 (61%) of pre-M
and 72 (59%) of post-M women. Pre-M women was observed to
have a more frequent occurrence of OFC than post-M women (23%
vs 14%; P ¼ .03). Moreover, post-M PHPT women had a higher
occurrence of hypertension (53% vs 25%; P < .0001) and GSD (28%
vs 19%; P ¼ 0.04) than pre-M PHPT women. However, other clinical
parameters, such as weakness and fatigue (57% vs 62%; P ¼ .33),
renal manifestation (52% vs 46%; P ¼ .24), anemia (59% vs 52%; P ¼
.20), proximal myopathy (15% vs 13%; P ¼ .49), pancreatitis (9.5% vs
8%; P ¼ .82), and psychiatric manifestations (12% vs 10%; P ¼ .68),
were comparable between the 2 groups.
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Fig. 1. Number of pre-M and post-M PHPT patients and trend of age, parathyroid hormone, and 25-hydroxyvitamin D levels in female PHPT patients in the last 15 years (2005-2019)
(www.indianphptregistry.com).
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Table 1
Comparison of Biochemical Parameters Between Premenopausal and Postmenopausal PHPT Patients
Parameters

Female PHPT (N ¼ 354)

Premenopausal PHPT (n ¼ 232) Postmenopausal PHPT (n ¼ 122)

P value

Serum calcium (8.6-10.2 mg/dL)
Serum phosphate (2.5 -4 mg/dL)
Serum alkaline phosphatase (40-129 IU/L) a
Plasma iPTH (15-65 pg/mL)a
Plasma 25-hydroxyvitamin D (Vitamin D deﬁciency <20 ng/mL)
Serum creatinine (0.5-1.2 mg/dL)
Urinary calcium (mg/24 h)
Preoperative localization, n (%)
Tumor weight (g)a

11.9 ± 1.54
2.61 ± 0.61
179 (119-501)
321 (168-916)
22.5 ± 15.8
0.99 ± 0.61
289.3 ± 268.9
338 (95.5%)
2.14 (0.85-5.50)

12.1 ± 1.60
2.56 ± 0.60
202 (125-612)
403 (180-1015)
20.0 ± 13.8
0.92 ± 0.57
294.4 ± 284.2
224 (96.5%)
2.46 (1.0-6.6)

.05
.18
.02
.02
.0001
.002
.51
.87
.12

11.7 ± 1.43
2.65 ± 0.58
145 (111-283)
246 (147-695)
27.1 ± 18.1
1.14 ± 0.65
262.2 ± 250.3
114 (93.4%)
1.9 (0.78-3.98)

Abbreviations: iPTH ¼ intact parathyroid hormone, PHPT ¼ primary hyperparathyroidism.
a
Data was presented as median (interquartile range) and Mann-Whitney U test was used for comparison between the groups.

Histopathological ﬁndings were similar in the pre-M and postM groups, with 340 (96%) having a single adenoma. One year
after parathyroidectomy, 9 (4.0%) pre-M and 2 (1.8%) post-M PHPT
patients had a persistent disease (P ¼ .27).

Biochemistry
Table 1 describes the biochemistry and hormonal proﬁle of both
groups. Pre-M PHPT women had signiﬁcantly higher median
plasma iPTH levels (403 [180-1015] vs 246 [147-695]; P ¼ .02) and
median serum ALP levels (202 [125-612] vs 145 [111-283]; P ¼ .02)
than post-M PHPT women. The mean values of serum albuminadjusted calcium (12.1 ± 1.60 vs 11.7 ± 1.43 mg/dL; P ¼ .05) was
marginally higher in pre-M women. The data of 25-hydroxyvitamin
D was only available for 220 pre-M and 115 post-M women. Post-M
women had a signiﬁcantly higher mean 25-hydroxyvitamin D level
than pre-M PHPT women (27.1 ± 18.1 vs 20.0 ± 13.8 ng/mL; P ¼
.0001). In addition, 45% (n ¼ 52) of post-M patients were vitamin D
deﬁcient (25-hydroxyvitamin D level <20 ng/mL) compared with
58% (n ¼ 127) of pre-M women (P ¼ .03). In pre-M women, the
mean plasma 25-hydroxyvitamin D levels progressively increased
from 18.4 ng/mL in 2005-2009 to 21.4 ng/mL in 2015-2019. In postM women, mean plasma 25-hydroxyvitamin D levels were higher,
although showed a similar temporal trend increasing from 22.1 ng/
mL in 2005-2009 to 29.4 ng/mL in 2015-2019. Overall, 25hydroxyvitamin D levels signiﬁcantly improved in the last 5 years
(2014-2019) compared with the ﬁrst cluster (2005-2009) in both
groups at our center (Fig. 1).
In pre-M women, median iPTH levels showed a progressive
decrease from 512 pg/mL in 2005-2009 to 287 pg/mL in 2015-2019.
A similar temporal trend was seen in post-M registrants with a
median iPTH decreasing from 453 pg/mL in 2005-2009 to 231 pg/
mL in 2015-2019 (Fig. 1). We did not observe a signiﬁcant change in
other biochemical parameters over the time.
Post-M PHPT patients had a signiﬁcantly higher mean serum
creatinine levels than pre-M PHPT patients (1.14 ± 0.65 vs 0.92 ±
0.57 mg/dL; P ¼ .002). No difference between pre-M and post-M
women was observed in serum phosphate (2.56 ± 0.60 vs 2.65 ±
0.58 mg/dL; P ¼ .18) (Table 1).

Discussion
We observed that while pre-M women predominated in the
registry, there was a distinct trend with an increasing number of
post-M women being registered, thereby increasing the average
age. Pre-M women had more severe bone disease and biochemical
variables than post-M women. Parathyroidectomy cured the disease in both groups. These ﬁndings differ from reports from the
USA and Europe, where post-M women comprise the majority
(50%-70%) of PHPT cases,8,21-23 and an estrogen deﬁciency might
inﬂuence the difference in clinical presentation in post-M women.
The estrogen deﬁciency in menopause plays a signiﬁcant role in the
development of osteoporosis which is typically diagnosed in
post-M women and also contributes to the higher percentage of
PHPT reported from Western populations. 15
In a multicenter study (duration, 2010-2016), Meng et al16 reported that the Chinese center (Changsha) had more symptomatic
disease than the USA center (New Brunswick) and also showed that
post-M women made up 41% of cases in Changsha and 58% at New
Brunswick. Pre-M patients comprised 25% and 17% at the Changsha
and New Brunswick centers, respectively. Studies from India and
other Asian countries reported that overall PHPT patients were
younger than the USA and European countries.3,10,24 The trend is
changing with the increasing prevalence of asymptomatic cases in
China and Brazil.2,25,26 Asymptomatic PHPT as well as patients with
milder symptoms have progressively increased at our center and in
the country in the last 10 years similarly in the line of other Asian
countries; however, younger symptomatic PHPT patients remain
more prevalent.27-29 We found that pre-M comprised 51% of the
total and 68% of female PHPT cases at our center. The potential
reason for the higher prevalence of pre-M patients or overall young
patients at our center is possibly due to the aggressive nature of the
disease in this part of the world, which is further aggravated due to
the associated severe vitamin D deﬁciency. The PHPT in India and
other developing countries are severe and aggressive compared
with Western populations. The majority of patients still present
with severe bone and kidney disease, which was previously reported from the USA and European countries in the 1970s.1,3,30
Eastern PHPT patients have a signiﬁcantly higher resected tumor
weight than Western PHPT patients. Molecular studies have also
reported a signiﬁcantly more dysregulation in Indian PHPT patients.31-33 The second possible explanation of an aggressive disease is the delay in diagnosis; however, that is not supported by the
literature, as in India, PHPT patients are diagnosed in the fourth

Postoperative Findings and Correlation of Tumor Weight With
Disease Indices
Parathyroid tumors were localized in 338 (95.5%) subjects.
Parathyroidectomy was performed if imaging was positive; the
remainder (n ¼ 16) were medically managed. The median duration
of follow-up was 12 (6-36) and 12 (5-24) months, in the pre-M and
post-M groups, respectively. The median tumor weight was higher
in pre-M women (2.46 [1.0-6.6] vs 1.9 [0.78-3.98] g; P ¼ .12). We
correlated the log transformed serum Ca, PTH, ALP, and 25-OHD
with the log transformed adenoma weight using a simple linear
regression analysis. We found that the serum calcium (r ¼ 0.268; P
< .0001), PTH (r ¼ 0.516; P < .0001), and ALP levels (r ¼ 0.335; P <
.0001) were positively correlated with the tumor weight. However,
we did not observe a signiﬁcant association between 25hydroxyvitamin D and adenoma weight (r ¼ -0.065, P ¼ .42).
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Table 2
Comparison of Different Studies for Premenopausal and Postmenopausal PHPT Patients
Author/Country

Proportion of female PHPT Symptomatic percentage Serum calcium (mg/dL) PTH (pg/mL)

Castellano et al, 2017, Italy15 Pre-M:
54 (16.7%)
Post-M:
270 (83.3%)
Pre-M:
Meng et al, 2018, China16
33 (37.9%)
Post-M:
54 (62.1%)
Pre-M:
Meng et al, 2018, USA16
28 (21.5%)
Post-M:
102 (78.5%)
India, 2020, (current study)
Pre-M:
232 (65.5%)
Post-M:
122 (34.5%)

35 (64.8%)

11.2 ± 1.0

117 (43.3%)

11.2 ± 1.2

25-OHD (ng/ml) Serum ALP (IU/L)

126.5 (96.8)
139 (137)
a

801.9 ± 637.6

a

31.8 ± 21.6

NA

28.1 ± 20.3

NA

13.9 ± 7.3

794 ± 1034a

NA

13.4 ± 2.7

NA

12.8 ± 2.2

503.2 ± 516.7

14.2 ± 8.3

166 ± 234

NA

11.2 ± 0.6

170.3 ± 156.5

26.7 ± 12.7

92 ± 42

NA

11.0 ± 0.5

122.8 ± 58.5

30.8 ± 10.9

83 ± 25

20.0 ± 13.8

202 (125-612)

27.1 ± 18.1a

145 (111-283)

213/232 (91.8%)

12.1 ± 1.60

403 (180-1015)

104/122 (85.2%)

11.7 ± 1.43

246 (147-695)

a

a

Abbreviations: ALP ¼ alanine phosphatase; NA ¼ not available, PHPT ¼ primary hyperparathyroidism; post-M ¼ postmenopausal; pre-M ¼ premenopausal; PTH ¼ parathyroid hormone; 25-OHD ¼ 25-hydroxyvitamin D.
a
Data between groups are statistically signiﬁcant.

pre-M women with PHPT had higher mean serum calcium and
PTH levels and lower 25-hydroxyvitamin D levels than post-M
women with PHPT at the Changsha (China) center, although no
difference was observed at the New Brunswick (USA) center
(Table 2).
We found that the menopause was not associated with the
increased renal manifestations; the higher serum creatinine levels
in post-M patients presumably reﬂect age-associated changes in
renal function. Previous studies have found that 10%-60% of women
with PHPT had renal manifestations.11,14-16 Meng et al16 also
showed that renal stones were more frequent in men, although
they did not observe any difference between pre- and post-M PHPT
women. However, renal stones were shown to be signiﬁcantly
higher in Changsha (China) than New Brunswick (USA) (54% vs
27%). The ﬁndings of our study on the renal manifestations in PHPT
are thus comparable to the report by Meng et al16 from the Chinese
center.
Furthermore, we have observed a higher rate of GSD in post-M
women. Previous studies from our center and others showed that
PHPT had a higher prevalence of GSD or cholelithiasis than the
general population.40-42 In general, women with older age are
associated with a higher prevalence of GSD.43 Therefore, these
factors together with hypercalcemia and high PTH might lead to
more GSD occurrence in post-M women with PHPT. However, the
exact cause and effect relationship is not well established.
To the best of literature search, this is the ﬁrst study to explore
the effects of menopause on the disease presentation, biochemical
variables, and severity in women with PHPT. The present study is a
retrospective single-center study that may have patient selection
bias; therefore, we need prospective multicenter study plans to
evaluate the direct effect of menopause on the disease presentation
and severity. Not all PHPT patients had DXA, and had they all had
DXA, perhaps the prevalence of bone disease would be higher than
reported in the current study.
In conclusion, in India, pre-M patients are the dominant population in PHPT; however, post-M PHPT patients are progressively
and signiﬁcantly increasing. Pre-M PHPT patients had more severe
bone disease with the biochemically more aggressive disease than
post-M PHPT patients.

decade, whereas in the USA and European countries, patients are
diagnosed in the sixth decade of life.1,3,21
Skeletal manifestations are more common in women, whereas
renal manifestations are more common in men with PHPT.11-14,34 In
symptomatic patients’ skeletal features include bone pain, skeletal
deformities, and pathological fractures reported in 40%-70% of
PHPT cases.3,24-26 We found that pre-M women had more severe
skeletal involvement (in the form of OFC) than post-M women. OFC
is now rarely reported from the Western countries and China with
the recent increase of asymptomatic cases.25,35. However, in
developing countries like India, skeletal problems are still prevalent
in individuals with PHPT.3,11,36 Furthermore, we observed that preM PHPT patients had higher median PTH and ALP levels than postM PHPT patients. The potential reason of the severe disease in preM women is multifactorial. One reason could be that the younger
skeleton responds more to the changes in PTH and vitamin D levels.
Same was also supported by the peak bone mass and bone turn
over markers in the third to fourth decades of life in the Indian
population due to higher bone formation.37 The mean age of pre-M
women in our cohort was 37 years. It might also lead to more bone
involvement in pre-M women, higher ALP levels, and tumor
weight. The second potential reason for the higher percentage of
pre-M women at our center as well as others from the region could
be selection bias as most patients are presented with symptoms;
however, in Western populations, most patients are diagnosed
during the routine biochemical screening. In recent times, the
awareness of bone diseases increased in the Indian population, and
routine biochemical screening signiﬁcantly increased in an older
population. The same is also evident in the study published by
Mithal et al29 that showed an increased prevalence of the asymptomatic disease.
Additionally, pre-M women have been observed to have more
vitamin D deﬁciency than post-M women. Post-M PHPT patients
have been observed to have higher 25-hydroxyvitamin D levels
than pre-M PHPT patients, in parallel with a progressive decrease
in iPTH levels. Higher 25-hydroxyvitamin D levels in post-M
PHPT women might be due to the rising trend of vitamin D
supplementation prescribed by physicians for better bone health
and more sunlight exposure. Bandeira et al38 revealed that patients with PHPT who had OFC were younger and had lower 25hydroxyvitamin D levels than patients with renal stones or who
were asymptomatic. Other studies from India and China have
also observed that patients with severe bone disease had severe
vitamin D deﬁciency.30,39 In the 2-center study of Meng et al16,
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The authors have no multiplicity of interest to disclose.
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